Your contact person
Manager PR & Communications Jan Phillip Denkers
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Evotec: € 7.5 m grant for development of COVID-19 therapeutic
Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...
Read more …
Indivumed Launches the nRavel AI Platform
Indivumed GmbH (“Indivumed”) today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines ...
Read more …
Evotec & Takeda: strategic RNA alliance
Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover ...
Read more …
Indivumed Announces Expansion
Indivumed GmbH (“Indivumed”) announced today the founding of Ix Therapeutics GmbH (“Ix Therapeutics”), a joint venture with Xlife Sciences AG (“Xlife Sciences”), which marks Indivumed’s ...
Read more …
Development partnership focused on oncology target
Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. ...
Read more …
Just - Evotec produce antibody products against COVID-19
Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to ...
Read more …
Indivumed’s multi-omics database IndivuType
More than 200 participants from around the globe, including fourteen of the top 20 pharma companies, numerous biotech companies, and members from leading academic cancer ...
Read more …